|
|
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
|
|
- Lethal congenital contractural syndrome (LCCS)
- Type I diabetes mellitus
|
|
|
ERBB4 |
erb-b2 receptor tyrosine kinase 4 |
|
- Afatinib
- Fostamatinib
- Brigatinib
- Zanubrutinib
|
|
|
|
F2RL1 |
F2R like trypsin receptor 1 |
- Peptide ligand-binding receptors
- G alpha (q) signalling events
|
|
|
|
|
FXR2 |
FMR1 autosomal homolog 2 |
|
|
|
|
|
GLP1R |
glucagon like peptide 1 receptor |
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- G alpha (s) signalling events
- Glucagon-type ligand receptors
- ADORA2B mediated anti-inflammatory cytokines production
|
- Glucagon
- Exenatide
- Liraglutide
- Albiglutide
- Dulaglutide
- Lixisenatide
- Semaglutide
|
|
|
|
GPR35 |
G protein-coupled receptor 35 |
- Class A/1 (Rhodopsin-like receptors)
|
- Furosemide
- Pyrantel
- Kynurenic Acid
|
|
|
|
HLA-DPB1 |
major histocompatibility complex, class II, DP beta 1 |
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- MHC class II antigen presentation
- PD-1 signaling
- Interferon gamma signaling
|
|
- Dilated cardiomyopathy (DCM)
|
|
|
HTR2C |
5-hydroxytryptamine receptor 2C |
- Serotonin receptors
- G alpha (q) signalling events
|
- Tramadol
- Ziprasidone
- Methysergide
- Cabergoline
- Amitriptyline
- Olanzapine
- Clozapine
- Mirtazapine
- Loxapine
- Promazine
- Cyproheptadine
- Imipramine
- Fluoxetine
- Chlorpromazine
- Chlorpromazine
- Haloperidol
- Nortriptyline
- Amoxapine
- Fenfluramine
- Lisuride
- Fluphenazine
- Trazodone
- Ergotamine
- Apomorphine
- Paroxetine
- Trimipramine
- Risperidone
- Propiomazine
- Minaprine
- Cyclobenzaprine
- Maprotiline
- Ergoloid mesylate
- Tegaserod
- Doxepin
- Nefazodone
- Desipramine
- Escitalopram
- Pergolide
- Dexfenfluramine
- Bromocriptine
- Ketamine
- Quetiapine
- Aripiprazole
- Chlorprothixene
- Clomipramine
- Paliperidone
- Yohimbine
- Methotrimeprazine
- Midomafetamine
- 4-Bromo-2,5-dimethoxyphenethylamine
- Lorcaserin
- Dapoxetine
- Lofexidine
- Epicept NP-1
- Sertindole
- Mianserin
- Pizotifen
- Asenapine
- Ocaperidone
- Dotarizine
- Deramciclane
- Agomelatine
- Esmirtazapine
- Captodiame
- Etoperidone
- Lorpiprazole
- Setiptiline
- Dihydroergocornine
- m-Chlorophenylpiperazine
- Gilteritinib
- Sarpogrelate
- Eplivanserin
- Tiapride
- Dihydroergocristine
- 2,5-Dimethoxy-4-ethylthioamphetamine
- Aripiprazole lauroxil
|
|
|
|
LAMA4 |
laminin subunit alpha 4 |
- Laminin interactions
- Laminin interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- MET activates PTK2 signaling
|
|
|
|
|
LINC01554 |
long intergenic non-protein coding RNA 1554 |
|
|
|
|
|
LMNA |
lamin A/C |
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
|
|
LRCH4 |
leucine rich repeats and calponin homology domain containing 4 |
|
|
|
|
|
LRPAP1 |
LDL receptor related protein associated protein 1 |
|
|
|
|
|
MBP |
myelin basic protein |
- EGR2 and SOX10-mediated initiation of Schwann cell myelination
|
|
|
|
|
NAPA |
NSF attachment protein alpha |
- COPII-mediated vesicle transport
- Golgi Associated Vesicle Biogenesis
- COPI-mediated anterograde transport
- COPI-dependent Golgi-to-ER retrograde traffic
- Intra-Golgi traffic
- Retrograde transport at the Trans-Golgi-Network
|
|
|
|
|
NR4A1 |
nuclear receptor subfamily 4 group A member 1 |
- AKT phosphorylates targets in the nucleus
- Nuclear Receptor transcription pathway
- Constitutive Signaling by AKT1 E17K in Cancer
|
|
|
|
|
PLEKHF2 |
pleckstrin homology and FYVE domain containing 2 |
|
|
|
|
|
POT1 |
protection of telomeres 1 |
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Cleavage of the damaged purine
- Meiotic synapsis
- Packaging Of Telomere Ends
- Telomere Extension By Telomerase
- Polymerase switching on the C-strand of the telomere
- Processive synthesis on the C-strand of the telomere
- Telomere C-strand (Lagging Strand) Synthesis
- Telomere C-strand synthesis initiation
- Removal of the Flap Intermediate from the C-strand
- DNA Damage/Telomere Stress Induced Senescence
- Inhibition of DNA recombination at telomere
|
|
|
|
|
PRR13 |
proline rich 13 |
|
|
|
|
|
RAB33A |
RAB33A, member RAS oncogene family |
- TBC/RABGAPs
- RAB geranylgeranylation
|
|
|